
51 - 200 employés
Fondée en 2019
🧬 Biotechnologie
💊 Pharmaceutique
🔬 Science
💰 €85 000 000 Series B en 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics est une entreprise biopharmaceutique en phase clinique, axée sur le patient, qui développe des thérapies cellulaires pour les patients souffrant de maladies auto-immunes. L'entreprise est pionnière dans les thérapies CAR T-cell, tirant parti du pouvoir transformationnel des cellules T pour potentiellement offrir une rémission durable sans traitement pour les maladies auto-immunes. Le principal candidat de thérapie CAR T-cell de Kyverna, KYV-101, progresse à travers des essais cliniques ciblant diverses maladies auto-immunes, y compris la sclérose en plaques, la myasthénie grave, la sclérodermie systémique et la néphrite lupique. Leur pipeline comprend des thérapies innovantes utilisant des récepteurs antigéniques chimériques (CAR) T-cell, tant dans les formats autologues qu'allogéniques, destinées aux maladies auto-immunes médiées par les cellules B.
🕒 il y a 1 mois
🗣️🇺🇸🇬🇧 Anglais requis
Améliorez vos chances d'obtenir un entretien en vérifiant votre score de CV avant de postuler.

51 - 200 employés
Fondée en 2019
🧬 Biotechnologie
💊 Pharmaceutique
🔬 Science
💰 €85 000 000 Series B en 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics est une entreprise biopharmaceutique en phase clinique, axée sur le patient, qui développe des thérapies cellulaires pour les patients souffrant de maladies auto-immunes. L'entreprise est pionnière dans les thérapies CAR T-cell, tirant parti du pouvoir transformationnel des cellules T pour potentiellement offrir une rémission durable sans traitement pour les maladies auto-immunes. Le principal candidat de thérapie CAR T-cell de Kyverna, KYV-101, progresse à travers des essais cliniques ciblant diverses maladies auto-immunes, y compris la sclérose en plaques, la myasthénie grave, la sclérodermie systémique et la néphrite lupique. Leur pipeline comprend des thérapies innovantes utilisant des récepteurs antigéniques chimériques (CAR) T-cell, tant dans les formats autologues qu'allogéniques, destinées aux maladies auto-immunes médiées par les cellules B.
• Develop and execute channel strategies that balance customer experience, operational efficiency, compliance requirements, and gross-to-net (GTN) optimization. • Serve as business owner for third-party logistics (3PL) partnerships and distribution operations supporting CAR T commercialization. • Lead specialty pharmacy and distribution strategy development to support current and future portfolio needs. • Partner with Market Access, Finance, Commercial, and Legal teams to evaluate channel design alternatives and their impact on GTN performance. • Assess channel economics and recommend strategies that optimize reimbursement, contracting, distribution costs, and commercial profitability while maintaining customer satisfaction. • Oversee state licensing strategy, renewals, compliance requirements, and regulatory readiness. • Support government pricing activities through cross-functional coordination, process governance, and operational oversight. • Lead distribution governance, service-level management, and operational performance reviews across external partners. • Support launch planning, market expansion, and new product introductions through scalable channel infrastructure. • Develop reporting, analytics, and performance metrics that provide visibility into channel effectiveness and operational health. • Identify and mitigate operational, regulatory, and commercial risks across the distribution network.
• Bachelor’s degree required; advanced degree preferred. • 10+ years of experience in biotechnology, pharmaceutical, specialty distribution, market access, commercial operations, or related functions. • Experience developing and executing channel strategies for specialty pharmaceuticals, cell therapies, gene therapies, or other complex therapies. • Strong understanding of gross-to-net (GTN) principles, channel economics, distribution agreements, and commercial contracting. • Demonstrated ability to design channel solutions that optimize GTN performance while meeting customer, provider, and patient requirements.
• bonus • benefits • participation in Company’s stock plan
Postuler Maintenant🕒 il y a 1 mois
Director of Global Operations overseeing Nikkiso Cryogenic Services operations across global markets. Leading collaboration, standardization, and continuous improvement in operational activities.
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 1 mois
VP of Digital Transformation Operations at Patriot Bank managing significant initiatives in a dynamic banking environment. Collaborating with leadership to drive innovation and operational modernization.
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 1 mois
Terminal Operations Engineer providing engineering advisory services for oil and gas projects. Responsible for technical due diligence and validation in support of U.S. Department of Energy initiatives.
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 1 mois
Director, Business Services for Medicaid Operations at Model N empowering life sciences and high-tech clients. Delivering exceptional service and driving operational excellence in the pharmaceutical industry.
🇺🇸 États-Unis – Télétravail
💵 $150 000 - $195 000 / an
⏰ Temps Plein
🔴 Expert
⚙️ Opérations
🦅 Parrain de Visa H1B
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 1 mois
Director of Sales Operations leading operational strategy for Megaport's compute-focused products. Responsible for systems scaling, forecasting, and sales analytics within a high-growth tech environment.
🗣️🇺🇸🇬🇧 Anglais requis